FluMist
2012-2013 Flu Season Drawing to a Close »
" Flu activity is continuing to decline, according to this week's FluView, which reports that influenza-like-illness (ILI) in the United States has fallen below baseline for the first time since early December. Other indicators are declining as we"...
FluMist
INDICATIONS
FluMist is a vaccine indicated for the active immunization of individuals 2-49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
DOSAGE AND ADMINISTRATION
FOR INTRANASAL ADMINISTRATION BY A HEALTH CARE PROVIDER.
Dosing Information
FluMist should be administered according to the following schedule:
| Age Group | Vaccination Status | Dosage Schedule |
| Children age 2 years through 8 years | Not previously vaccinated with influenza vaccine | 2 doses (0.2 mL* each, at least 1 month apart) |
| Children age 2 years through 8 years | Previously vaccinated with influenza vaccine | 1 dose (0.2 mL*) |
| Children, adolescents, and adults age 9 through 49 years | Not applicable | 1 dose (0.2 mL*) |
| *Administer as 0.1 mL per nostril. | ||
For children age 2 years through 8 years who have not previously received influenza vaccine, the recommended dosage schedule for nasal administration is one 0.2 mL dose (0.1 mL per nostril), followed by a second 0.2 mL dose (0.1 mL per nostril) given at least 1 month later.
For all other individuals, including children age 2-8 years who have previously received influenza vaccine, the recommended schedule is one 0.2 mL dose (0.1 mL per nostril).
FluMist should be administered prior to exposure to influenza. Annual revaccination with influenza vaccine is recommended.
Administration Instructions
Each sprayer contains a single dose of FluMist; approximately one-half of the contents should be administered into each nostril. Refer to the administration diagram (Figure 1) for step-by-step administration instructions. Once FluMist has been administered, the sprayer should be disposed of according to the standard procedures for medical waste (e.g., sharps container or biohazard container).
Figure 1
![]() |
Note: Active inhalation (i.e., sniffing) is not required by the patient during FluMist administration.
HOW SUPPLIED
Dosage Forms And Strengths
0.2 mL pre-filled, single-use intranasal spray.
Each 0.2 mL dose of FluMist is formulated to contain 106.5-7.5 FFU (fluorescent focus units) of each of three live attenuated influenza virus reassortants: A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008.
FluMist is supplied for intranasal delivery in a package of 10 pre-filled, single-use sprayers. The singleuse intranasal sprayer contains no latex.
NDC 66019-109-10
Storage and Handling
Once FluMist has been administered, the sprayer should be disposed of according to the standard procedures for medical waste (e.g., sharps container or biohazard container).
FLUMIST SHOULD BE STORED IN A REFRIGERATOR BETWEEN 2-8°C (35-46°F) UPON RECEIPT AND UNTIL USE. THE PRODUCTMUST BE USED BEFORE THE EXPIRATION DATE ON THE SPRAYER LABEL. DO NOT FREEZE.
The cold chain (2 to 8°C) must be maintained when transporting FluMist.
Manufactured by: MedImmune, LLC, Gaithersburg, MD 20878. Issue Date: May 2011
Last reviewed on RxList: 1/10/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional FluMist Information
FluMist - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.







